Analysts Anticipate Ultragenyx Pharmaceutical Inc (RARE) Will Post Quarterly Sales of $10.20 Million

Equities analysts predict that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will report $10.20 million in sales for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have made estimates for Ultragenyx Pharmaceutical’s earnings, with estimates ranging from $4.91 million to $18.92 million. Ultragenyx Pharmaceutical reported sales of $200,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 5,000%. The company is expected to issue its next earnings report on Thursday, November 1st.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year sales of $46.49 million for the current year, with estimates ranging from $25.22 million to $72.18 million. For the next financial year, analysts forecast that the company will report sales of $99.94 million, with estimates ranging from $74.10 million to $143.68 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.08) by $1.02. Ultragenyx Pharmaceutical had a negative return on equity of 44.09% and a negative net margin of 703.27%. The firm had revenue of $12.79 million for the quarter, compared to analysts’ expectations of $5.63 million. During the same period last year, the firm earned ($1.72) EPS.

A number of research analysts have weighed in on RARE shares. Canaccord Genuity raised their target price on shares of Ultragenyx Pharmaceutical from $80.00 to $90.00 and gave the stock a “buy” rating in a research note on Friday, August 3rd. Robert W. Baird reiterated a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, August 3rd. BidaskClub downgraded shares of Ultragenyx Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 25th. JPMorgan Chase & Co. restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 29th. Finally, JMP Securities reiterated a “buy” rating and set a $94.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Sunday, September 2nd. One analyst has rated the stock with a sell rating, five have given a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical has an average rating of “Buy” and an average target price of $85.53.

Shares of Ultragenyx Pharmaceutical stock opened at $63.28 on Friday. Ultragenyx Pharmaceutical has a twelve month low of $41.67 and a twelve month high of $90.98. The stock has a market capitalization of $3.31 billion, a P/E ratio of -8.44 and a beta of 1.95.

In other news, CFO Shalini Sharp sold 6,700 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $90.07, for a total value of $603,469.00. Following the transaction, the chief financial officer now directly owns 56,828 shares of the company’s stock, valued at $5,118,497.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director William Aliski sold 3,750 shares of the business’s stock in a transaction that occurred on Wednesday, August 8th. The shares were sold at an average price of $76.66, for a total transaction of $287,475.00. Following the transaction, the director now directly owns 72,610 shares in the company, valued at $5,566,282.60. The disclosure for this sale can be found here. Insiders have sold a total of 35,000 shares of company stock worth $2,700,774 over the last 90 days. 8.40% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 3.8% in the second quarter. BlackRock Inc. now owns 4,389,350 shares of the biopharmaceutical company’s stock worth $337,408,000 after buying an additional 158,723 shares during the last quarter. Federated Investors Inc. PA grew its holdings in shares of Ultragenyx Pharmaceutical by 18.2% in the 2nd quarter. Federated Investors Inc. PA now owns 1,417,551 shares of the biopharmaceutical company’s stock worth $108,967,000 after purchasing an additional 218,060 shares during the last quarter. First Trust Advisors LP grew its holdings in shares of Ultragenyx Pharmaceutical by 1.7% in the 2nd quarter. First Trust Advisors LP now owns 977,505 shares of the biopharmaceutical company’s stock worth $75,141,000 after purchasing an additional 16,713 shares during the last quarter. Northern Trust Corp lifted its position in Ultragenyx Pharmaceutical by 6.7% during the 2nd quarter. Northern Trust Corp now owns 554,092 shares of the biopharmaceutical company’s stock worth $42,594,000 after buying an additional 34,942 shares in the last quarter. Finally, Voya Investment Management LLC lifted its position in Ultragenyx Pharmaceutical by 2,221.4% during the 2nd quarter. Voya Investment Management LLC now owns 426,788 shares of the biopharmaceutical company’s stock worth $32,807,000 after buying an additional 408,403 shares in the last quarter. Hedge funds and other institutional investors own 96.11% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Read More: Rule of 72

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply